Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.2 Million CAD | 162.93% |
| 2022 | 456.79 Thousand CAD | 1396.65% |
| 2021 | 30.52 Thousand CAD | 74.61% |
| 2020 | 17.48 Thousand CAD | 20.57% |
| 2019 | 14.49 Thousand CAD | -61.9% |
| 2018 | 38.05 Thousand CAD | -84.58% |
| 2017 | 246.84 Thousand CAD | -18.47% |
| 2016 | 302.77 Thousand CAD | 9297.21% |
| 2015 | 3222.00 CAD | -73.82% |
| 2014 | 12.3 Thousand CAD | -85.24% |
| 2013 | 83.36 Thousand CAD | 0.0% |
| 2012 | 83.36 Thousand CAD | 67.72% |
| 2011 | 49.7 Thousand CAD | -76.25% |
| 2010 | 209.24 Thousand CAD | 263.44% |
| 2009 | 57.57 Thousand CAD | -37.29% |
| 2008 | 91.8 Thousand CAD | 1.64% |
| 2007 | 90.32 Thousand CAD | 11.23% |
| 2006 | 81.2 Thousand CAD | -8.96% |
| 2005 | 89.19 Thousand CAD | 877.04% |
| 2004 | -11.47 Thousand CAD | -332.7% |
| 2003 | 4933.00 CAD | 37.83% |
| 2002 | 3579.00 CAD | 0.0% |
| 2001 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 370.77 Thousand CAD | -23.4% |
| 2024 Q1 | 484.06 Thousand CAD | -3.36% |
| 2023 Q2 | 229.47 Thousand CAD | 73.28% |
| 2023 Q4 | 500.87 Thousand CAD | 91.34% |
| 2023 Q3 | 261.77 Thousand CAD | 14.08% |
| 2023 FY | 1.2 Million CAD | 162.93% |
| 2023 Q1 | 132.42 Thousand CAD | -21.57% |
| 2022 FY | 456.79 Thousand CAD | 1396.65% |
| 2022 Q1 | 15.11 Thousand CAD | 62.21% |
| 2022 Q2 | 56.87 Thousand CAD | 276.33% |
| 2022 Q3 | 215.96 Thousand CAD | 279.72% |
| 2022 Q4 | 168.84 Thousand CAD | -21.82% |
| 2021 Q2 | -998.00 CAD | -160.6% |
| 2021 FY | 30.52 Thousand CAD | 74.61% |
| 2021 Q3 | 20.55 Thousand CAD | 2159.62% |
| 2021 Q4 | 9317.00 CAD | -54.67% |
| 2021 Q1 | 1647.00 CAD | -25.81% |
| 2020 FY | 17.48 Thousand CAD | 20.57% |
| 2020 Q4 | 2220.00 CAD | -53.33% |
| 2020 Q3 | 4757.00 CAD | -3.14% |
| 2020 Q2 | 4911.00 CAD | -12.18% |
| 2020 Q1 | 5592.00 CAD | 119.83% |
| 2019 FY | 14.49 Thousand CAD | -61.9% |
| 2019 Q3 | 12.23 Thousand CAD | -32.19% |
| 2019 Q2 | 18.03 Thousand CAD | 45.11% |
| 2019 Q1 | 12.43 Thousand CAD | 116.72% |
| 2019 Q4 | -28.2 Thousand CAD | -330.58% |
| 2018 FY | 38.05 Thousand CAD | -84.58% |
| 2018 Q4 | -74.33 Thousand CAD | 23.87% |
| 2018 Q3 | -97.65 Thousand CAD | -187.1% |
| 2018 Q2 | 112.11 Thousand CAD | 14.48% |
| 2018 Q1 | 97.92 Thousand CAD | 90.89% |
| 2017 Q3 | 78.33 Thousand CAD | 67.6% |
| 2017 FY | 246.84 Thousand CAD | -18.47% |
| 2017 Q1 | 70.47 Thousand CAD | 156.63% |
| 2017 Q2 | 46.73 Thousand CAD | -33.68% |
| 2017 Q4 | 51.3 Thousand CAD | -34.51% |
| 2016 Q1 | 202.34 Thousand CAD | 480.19% |
| 2016 FY | 302.77 Thousand CAD | 9297.21% |
| 2016 Q2 | 46.01 Thousand CAD | -77.26% |
| 2016 Q4 | -124.44 Thousand CAD | -169.58% |
| 2016 Q3 | 178.85 Thousand CAD | 288.66% |
| 2015 FY | 3222.00 CAD | -73.82% |
| 2015 Q4 | 34.87 Thousand CAD | -41.99% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | 3222.00 CAD | 0.0% |
| 2015 Q3 | 60.12 Thousand CAD | 1766.08% |
| 2014 Q3 | - CAD | -100.0% |
| 2014 Q2 | 83.36 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | 12.3 Thousand CAD | -85.24% |
| 2014 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | -100.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | 83.36 Thousand CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | 83.36 Thousand CAD | 0.0% |
| 2012 FY | 83.36 Thousand CAD | 67.72% |
| 2012 Q2 | 61.98 Thousand CAD | 3539.84% |
| 2012 Q3 | - CAD | -100.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | -1802.00 CAD | -121.87% |
| 2011 Q1 | 10.45 Thousand CAD | -96.17% |
| 2011 FY | 49.7 Thousand CAD | -76.25% |
| 2011 Q3 | 14.93 Thousand CAD | -9.93% |
| 2011 Q4 | 8239.00 CAD | -44.85% |
| 2011 Q2 | 16.58 Thousand CAD | 58.7% |
| 2010 Q2 | -165.73 Thousand CAD | -262.46% |
| 2010 Q3 | 14.33 Thousand CAD | 108.65% |
| 2010 Q1 | 102.01 Thousand CAD | -61.52% |
| 2010 Q4 | 272.96 Thousand CAD | 1804.2% |
| 2010 FY | 209.24 Thousand CAD | 263.44% |
| 2009 Q1 | 17.48 Thousand CAD | 154.68% |
| 2009 Q2 | 15.42 Thousand CAD | -11.78% |
| 2009 Q3 | 7875.00 CAD | -48.96% |
| 2009 Q4 | 265.09 Thousand CAD | 3266.23% |
| 2009 FY | 57.57 Thousand CAD | -37.29% |
| 2008 FY | 91.8 Thousand CAD | 1.64% |
| 2008 Q4 | 6867.00 CAD | -61.4% |
| 2008 Q3 | 17.79 Thousand CAD | -36.97% |
| 2008 Q2 | 28.22 Thousand CAD | 21.68% |
| 2008 Q1 | 23.19 Thousand CAD | 13.0% |
| 2007 Q3 | 19.85 Thousand CAD | 12.23% |
| 2007 Q2 | 17.69 Thousand CAD | -39.56% |
| 2007 Q1 | 29.27 Thousand CAD | 22.29% |
| 2007 Q4 | 20.52 Thousand CAD | 3.37% |
| 2007 FY | 90.32 Thousand CAD | 11.23% |
| 2006 Q4 | 23.93 Thousand CAD | 23.3% |
| 2006 Q1 | 16.05 Thousand CAD | -24.3% |
| 2006 Q2 | 22.19 Thousand CAD | 38.24% |
| 2006 Q3 | 19.41 Thousand CAD | -12.51% |
| 2006 FY | 81.2 Thousand CAD | -8.96% |
| 2005 Q1 | 24.44 Thousand CAD | 144.55% |
| 2005 Q2 | 32.54 Thousand CAD | 33.14% |
| 2005 Q3 | 21.75 Thousand CAD | -33.14% |
| 2005 Q4 | 21.2 Thousand CAD | -2.55% |
| 2005 FY | 89.19 Thousand CAD | 877.04% |
| 2004 FY | -11.47 Thousand CAD | -332.7% |
| 2004 Q4 | 9996.00 CAD | -59.27% |
| 2004 Q3 | 24.54 Thousand CAD | 161.13% |
| 2004 Q2 | -40.15 Thousand CAD | -230.76% |
| 2004 Q1 | 30.7 Thousand CAD | 352.42% |
| 2003 Q1 | 225.00 CAD | 0.0% |
| 2003 Q4 | 6787.00 CAD | 0.0% |
| 2003 Q3 | - CAD | -100.0% |
| 2003 FY | 4933.00 CAD | 37.83% |
| 2003 Q2 | 3767.00 CAD | 1574.22% |
| 2002 Q4 | - CAD | -100.0% |
| 2002 FY | 3579.00 CAD | 0.0% |
| 2002 Q3 | 632.00 CAD | 0.0% |
| 2001 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 723.521% |
| Arrayit Corporation | 2.57 Million USD | 53.267% |
| Atlantic International Corp. | -154.23 Thousand USD | 880.24% |
| Biocept, Inc. | -2.58 Million USD | 146.607% |
| Bioqual, Inc. | 7.42 Million USD | 83.802% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | -336.013% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 99.982% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 32.924% |
| iMD Companies, Inc. | -23.63 Thousand USD | 5191.154% |
| IDenta Corp. | 662.97 Thousand USD | -81.515% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 94.778% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | -1451.348% |
| InVitro International | 635.98 Thousand USD | -89.218% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 81.664% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | -10.132% |
| NovelStem International Corp. | 12 Thousand USD | -9928.3% |
| Optigenex Inc. | -102.96 Thousand USD | 1268.731% |
| PharmChem, Inc. | 3.9 Million USD | 69.178% |
| Proteome Sciences plc | 2.09 Million USD | 42.603% |
| Response Genetics, Inc | 3.94 Million USD | 69.472% |
| Rennova Health, Inc. | 6.26 Million USD | 80.802% |
| RushNet, Inc. | 1.1 Million USD | -8.943% |
| ScreenPro Security Inc. | 856.57 Thousand USD | -40.489% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 398.057% |
| Todos Medical Ltd. | 4.31 Million USD | 72.079% |